<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117779">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569737</url>
  </required_header>
  <id_info>
    <org_study_id>2914-012</org_study_id>
    <nct_id>NCT01569737</nct_id>
  </id_info>
  <brief_title>Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella</brief_title>
  <acronym>ellipse II</acronym>
  <official_title>Prospective Multicenter Observational Study to Assess Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies
      exposed to ella, whether due to failure of the emergency contraception or inadvertent
      exposure during pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy outcome</measure>
    <time_frame>up to 9 months after pregnancy diagnosis</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Emergency Contraception</condition>
  <arm_group>
    <arm_group_label>ella</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ella</intervention_name>
    <description>ella, single intake, tablet 30mg</description>
    <arm_group_label>ella</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who have been exposed to ella during the menstrual cycle in which the
        pregnancy started or at any time during pregnancy will be enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Pregnant women, exposed to ella during the menstrual cycle in which the pregnancy
             started (treatment failure) or at any time during pregnancy (inadvertent exposure
             during pregnancy)

          -  Adolescents and/or adults in the USA, depending on the respective State law
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood Gulf Coast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Fine, MD</last_name>
    <phone>+17138316553</phone>
    <email>Paul.Fine@ppgulfcoast.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Planned Parenthood Federation of America, Inc</name>
      <address>
        <city>New York,</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>September 18, 2014</lastchanged_date>
  <firstreceived_date>March 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ella</keyword>
  <keyword>ulipristal acetate</keyword>
  <keyword>pregnancy</keyword>
  <keyword>emergency contraception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
